Tentarix is focused on modalities that have cell specific function and has built a team that aims to transform biologics.

In August 2023, the company entered into three, multi-year, collaborations with Gilead Sciences, aiming to leverage its proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory disease.